Increase in Growth for Global Cattle Industry Predicted at World Buiatrics Congress

Bayer Animal Health Encourages Collaboration and Facilitates Global Foresight Into Transforming Cattle Production

MONHEIM, Germany, November 15, 2010 - Bayer Animal Health today outlined their vision for the future of cattle
production at the 26th World Buiatrics Congress in Santiago, Chile. At the
scientific symposium, Bayer confirmed their commitment to transforming
livestock production through bringing together world cattle industry thought
leaders alongside their expert scientists. Presentations demonstrated how new
approaches to livestock production will help veterinarians and producers meet
the demands of the rapidly changing global market.

After the negative impact of the global financial crisis on the meat
industry in 2009, world experts presenting at the 3rd International Bayer
Cattle Symposium gave hope to producers worldwide, covering subjects from
production trends over the next 40 years to the transformative power of
effective parasite and nutrient management systems.

Dr Osler Desouzart, OD Consulting Brazil and a member of the Advisory
Board of the World Agricultural Forum, presented predictions for global
population growth and consumption over the next 40 years. His research
concluded that the dramatic increase in population growth will drive
continued growth in meat consumption. Dr Desouzart predicts that "looking
towards 2050, the meat consumption could possibly double compared to 2008."

According to Dr Desouzart, adapting to the changing demands will be
imperative if the meat industry is to meet the new markets' needs, as well as
keeping pace with demand from traditional markets. Furthermore, consumer
attitudes in the developed world are changing. "Today's consumers want to
know what they eat, where does it come from, how it was produced. They want
assurances that it is safe for their health as well as for the environment.
Meat should come from animals that are well cared for and are healthy. Animal
health is no longer a subject solely for veterinarians, it has become a core
value for the consumer", concluded Dr Desouzart.

This new consciousness in meat consumption was highlighted in a
presentation by Jerome Lyman, Corporate Vice President of Global Quality
Systems, McDonalds, US. "Our customers value the place of beef in their diet;
however, they are also expressing concerns about issues such as zoonoses and
the production methods used in the food chain. McDonalds has long been at the
forefront of efforts to rationalise anti-infective use and we are seeing
these attitudes increasingly taking hold across the food industry. Cattle
producers need to be able to demonstrate that their products meet the highest
safety standards to match the consumers' drive to quality", said Mr Lyman.

The central role of animal health in successful livestock production was
also reflected in the presentations of Drs Nicholas Jonsson of the University
of Glasgow, Scotland, and Marcelo Molento of the Universidade Federal do
Parana, Brazil, who discussed the need for new approaches to parasite
control. Veterinarians should understand the needs of producers regarding
ectoparasite control and work with them focussing their specific needs. Dr
Jonsson said, "All too often cattle producers are not looking to
veterinarians when it comes to parasite control programmes, leading to
suboptimal results. This is a waste of time and money and undermines the
welfare of their livestock. Veterinarians should help their clients and work
with them on tailored programmes that give optimal, cost-effective control",
said Dr Jonsson. Dr Molento focused on the impact of technology transfer to
improve endoparasite control in cattle production worldwide. "A clear example
of the potential impact comes from scientific literature where effective
endoparasite control can be seen with Eimeria spp. infection in cattle. These
parasites cause considerable economic damage to the cattle industry. Yet we
know that preventative treatment with toltrazuril in calves prevents disease
and leads to significant increases in weight gain in both dairy and beef
cattle", said Dr Molento.

Jim Gerardot, Head of Global Marketing - Food Animal Products, Bayer
Animal Health, said, "Bayer Animal Health continues to invest in research.
With this knowledge, we are able to offer our customers the best possible
solutions to meet their needs and provide education to ensure they can
maximise the benefits. The research presented at WBC is another example of
our global commitment to doing all we can to support the continuing
transformation of livestock production to ensure a bright future for all our
customers."

About Bayer HealthCare AG

The Bayer Group is a global enterprise with core competencies in the
fields of health care, nutrition and high-tech materials. Bayer HealthCare
AG, a subsidiary of Bayer AG with annual sales of about EUR 15.9 billion
(2009), is one of the world's leading, innovative companies in the healthcare
and medical products industry and is based in Leverkusen, Germany. The
company combines the global activities of the Animal Health, Consumer Care,
Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com

With a turnover of EUR 977 million (2009) Bayer HealthCare's Animal
Health Division is one of the world's leading manufacturers of veterinary
drugs. The division manufactures and markets more than 100 different
veterinary drugs and care products for livestock and companion animals.

Forward-Looking Statements

This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our annual and interim reports to the
Frankfurt Stock Exchange and in our reports filed with the U.S. Securities
and Exchange Commission (including our Form 20-F). The company assumes no
liability whatsoever to update these forward-looking statements or to confirm
them to future events or developments.

    Contact:

    Kathrin Statz
    +49-2173-38-4019
    kathrin.statz@bayerhealthcare.com

Contact: Kathrin Statz, +49-2173-38-4019, kathrin.statz at bayerhealthcare.com